These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
423 related articles for article (PubMed ID: 15813510)
1. Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer. Bundred N Cancer Invest; 2005; 23(2):173-81. PubMed ID: 15813510 [TBL] [Abstract][Full Text] [Related]
2. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy. McKeage K; Curran MP; Plosker GL Drugs; 2004; 64(6):633-48. PubMed ID: 15018596 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness and tolerability of fulvestrant in postmenopausal women with hormone receptor-positive breast cancer. Jones SE; Pippen J Clin Breast Cancer; 2005 Apr; 6 Suppl 1():S9-14. PubMed ID: 15865850 [TBL] [Abstract][Full Text] [Related]
4. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole. Carlson RW; Henderson IC Breast Cancer Res Treat; 2003; 80 Suppl 1():S19-26; discussion S27-8. PubMed ID: 14535531 [TBL] [Abstract][Full Text] [Related]
5. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Robertson JF; Osborne CK; Howell A; Jones SE; Mauriac L; Ellis M; Kleeberg UR; Come SE; Vergote I; Gertler S; Buzdar A; Webster A; Morris C Cancer; 2003 Jul; 98(2):229-38. PubMed ID: 12872340 [TBL] [Abstract][Full Text] [Related]
6. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Robertson JFR; Bondarenko IM; Trishkina E; Dvorkin M; Panasci L; Manikhas A; Shparyk Y; Cardona-Huerta S; Cheung KL; Philco-Salas MJ; Ruiz-Borrego M; Shao Z; Noguchi S; Rowbottom J; Stuart M; Grinsted LM; Fazal M; Ellis MJ Lancet; 2016 Dec; 388(10063):2997-3005. PubMed ID: 27908454 [TBL] [Abstract][Full Text] [Related]
7. Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy. Vergote I; Robertson JF; Kleeberg U; Burton G; Osborne CK; Mauriac L; ; Breast Cancer Res Treat; 2003 May; 79(2):207-11. PubMed ID: 12825855 [TBL] [Abstract][Full Text] [Related]
8. A new estrogen receptor antagonist--an overview of available data. Jones SE Breast Cancer Res Treat; 2002 Oct; 75 Suppl 1():S19-21; discussion S33-5. PubMed ID: 12353819 [TBL] [Abstract][Full Text] [Related]
9. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. Howell A; Robertson JF; Abram P; Lichinitser MR; Elledge R; Bajetta E; Watanabe T; Morris C; Webster A; Dimery I; Osborne CK J Clin Oncol; 2004 May; 22(9):1605-13. PubMed ID: 15117982 [TBL] [Abstract][Full Text] [Related]
10. Fulvestrant in the treatment of postmenopausal women with advanced breast cancer. Gradishar W Expert Rev Anticancer Ther; 2005 Jun; 5(3):445-53. PubMed ID: 16001952 [TBL] [Abstract][Full Text] [Related]
11. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. Osborne CK; Pippen J; Jones SE; Parker LM; Ellis M; Come S; Gertler SZ; May JT; Burton G; Dimery I; Webster A; Morris C; Elledge R; Buzdar A J Clin Oncol; 2002 Aug; 20(16):3386-95. PubMed ID: 12177098 [TBL] [Abstract][Full Text] [Related]
12. A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer. Dodwell D; Vergote I Cancer Treat Rev; 2005 Jun; 31(4):274-82. PubMed ID: 15908126 [TBL] [Abstract][Full Text] [Related]
13. Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials. Vergote I; Robertson JF Br J Cancer; 2004 Mar; 90 Suppl 1(Suppl 1):S11-4. PubMed ID: 15094759 [TBL] [Abstract][Full Text] [Related]
14. Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials. Mauriac L; Pippen JE; Quaresma Albano J; Gertler SZ; Osborne CK Eur J Cancer; 2003 Jun; 39(9):1228-33. PubMed ID: 12763210 [TBL] [Abstract][Full Text] [Related]
15. Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents. Vergote I; Abram P Ann Oncol; 2006 Feb; 17(2):200-4. PubMed ID: 16251200 [TBL] [Abstract][Full Text] [Related]
16. Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial. Xu B; Jiang Z; Shao Z; Wang J; Feng J; Song S; Chen Z; Gu K; Yu S; Zhang Y; Wang C; Zhang F; Yang J Cancer Chemother Pharmacol; 2011 Jan; 67(1):223-30. PubMed ID: 20938664 [TBL] [Abstract][Full Text] [Related]
17. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. Howell A; Robertson JF; Quaresma Albano J; Aschermannova A; Mauriac L; Kleeberg UR; Vergote I; Erikstein B; Webster A; Morris C J Clin Oncol; 2002 Aug; 20(16):3396-403. PubMed ID: 12177099 [TBL] [Abstract][Full Text] [Related]
18. Fulvestrant - a new treatment for postmenopausal women with hormone-sensitive advanced breast cancer. Possinger K Expert Opin Pharmacother; 2004 Dec; 5(12):2549-58. PubMed ID: 15571471 [TBL] [Abstract][Full Text] [Related]
19. Fulvestrant in postmenopausal women with advanced breast cancer. Bross PF; Baird A; Chen G; Jee JM; Lostritto RT; Morse DE; Rosario LA; Williams GM; Yang P; Rahman A; Williams G; Pazdur R Clin Cancer Res; 2003 Oct; 9(12):4309-17. PubMed ID: 14555500 [TBL] [Abstract][Full Text] [Related]
20. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Johnston SR; Kilburn LS; Ellis P; Dodwell D; Cameron D; Hayward L; Im YH; Braybrooke JP; Brunt AM; Cheung KL; Jyothirmayi R; Robinson A; Wardley AM; Wheatley D; Howell A; Coombes G; Sergenson N; Sin HJ; Folkerd E; Dowsett M; Bliss JM; Lancet Oncol; 2013 Sep; 14(10):989-98. PubMed ID: 23902874 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]